24559
In January of 2012 , vismodegib , a SMO antagonist , became the first agent to target the Hh pathway to receive approval by the United States Food and Drug Administration ( FDA ) after this agent showed remarkable activity in phase I and II trials for the treatment of BCC .
 Chemical: vismodegib
Please list all entity words in the text that fit the category.Output format is "type1: word1; type2: word2". 
Option: Chemical 
Text: {0} 
Answer:
 Chemical: vismodegib